MediVax AI's $45M Series C Fuels AI-Designed Vaccine Pipeline

MediVax AI has secured $45 million in a Series C round led by Khosla Ventures to advance its computationally designed vaccine candidates into human trials. The biotech leverages a proprietary AI platform to identify and optimize novel antigen targets, aiming to generate more potent and durable immune responses than traditional methods. Its lead candidate, MVX-101, is a prophylactic vaccine for cytomegalovirus (CMV) slated to enter a Phase 1/2 study in 2026, while MVX-201, a therapeutic candidate for HPV-associated cancers, is in late preclinical development. The new capital is earmarked specifically to complete IND-enabling studies for MVX-201 and to initiate the first-in-human trial for MVX-101. Khosla Ventures, known for its deep-tech and biotech platform bets, led the round, signaling strong belief in the underlying computational discovery engine. The financing arrives as investor interest grows in computational biology platforms that promise to de-risk and accelerate immunogen design.